Latest Period
Q1 2026
Security Snapshot
Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP) Institutional Ownership
CUSIP: 21833P301
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
107
Shares (Excl. Options)
12,828,485
Price
$9.39
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- CRBP on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 12,828,485
- Total 13F value
- $120,454,148
- Portfolio coverage rank
- 0%
- Share change
- -103,498
- Value change
- +$569,311
- Number of holders
- 107
- Shares outstanding
- 17,685,185
- SEC-reported price per share
- $12.15
- Insider filing price
- $12.15
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 21833P301.
- 107 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 100 to 107 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $107,809,776 to $120,454,148.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 107 institutions filings for Q1 2026.
Security key
21833P301
Latest holder period
Q1 2026
13F holders
107
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
CRBP full holder history
Corbus Pharmaceuticals Holdings, Inc. SEC filings
Corbus Pharmaceuticals Holdings, Inc. company facts
Corbus Pharmaceuticals Holdings, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 21833P301:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
CRBP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 13% | +4.2% | $24,434,598 | -$312,902 | 2,344,971 | -1.3% | Cormorant Asset Management, LP | 11 Dec 2025 |
| Aberdeen Group plc | 7.5% | $10,759,045 | 1,321,750 | Aberdeen Group plc | 31 Dec 2025 | |||
| CITADEL ADVISORS LLC | 5.3% | $12,405,011 | 980,610 | Kenneth Griffin | 04 Nov 2025 | |||
| ORBIMED ADVISORS LLC | 5.9% | $5,307,498 | 718,200 | OrbiMed Capital LLC | 31 Dec 2024 | |||
| VANGUARD GROUP INC | 4.9% | $4,136,516 | 599,495 | The Vanguard Group | 30 Jun 2025 | |||
| BlackRock, Inc. | 2.9% | $2,431,622 | 352,409 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 107 institutional investors reported holding 12,828,485 shares of Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP). This represents 73% of the company’s total 17,685,185 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
66%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 13% | 2,344,971 | 0% | 1.1% | $22,019,278 |
| ORBIMED ADVISORS LLC | 9.8% | 1,737,287 | +8.8% | 0.37% | $16,313,125 |
| Aberdeen Group plc | 7.5% | 1,321,750 | 0% | 0.02% | $12,411,233 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 734,106 | 0% | 0% | $6,893,255 |
| CITADEL ADVISORS LLC | 4.1% | 727,060 | -14% | 0% | $6,827,094 |
| Prosight Management, LP | 3.9% | 697,108 | +1.9% | 1.1% | $6,545,844 |
| DIADEMA PARTNERS LP | 2.5% | 439,957 | 1.8% | $4,131,196 | |
| Stonepine Capital Management, LLC | 2.2% | 383,462 | -1.7% | 3.2% | $3,600,708 |
| ARMISTICE CAPITAL, LLC | 2.1% | 364,000 | -32% | 0.11% | $3,417,960 |
| RENAISSANCE TECHNOLOGIES LLC | 2% | 346,998 | -2.1% | 0.01% | $3,258,311 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.9% | 333,415 | +46% | 0% | $3,130,767 |
| ADAR1 Capital Management, LLC | 1.9% | 331,781 | +16% | 0.19% | $3,115,424 |
| BlackRock, Inc. | 1.5% | 271,636 | +1.3% | 0% | $2,550,662 |
| Exome Asset Management LLC | 1.3% | 234,136 | +68% | 1.3% | $2,198,537 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 187,029 | +9.5% | 0% | $1,757,021 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 0.91% | 160,462 | -12% | 0% | $1,506,738 |
| MARSHALL WACE, LLP | 0.83% | 146,596 | +89% | 0% | $1,376,537 |
| DIMENSIONAL FUND ADVISORS LP | 0.77% | 136,602 | +77% | 0% | $1,281,362 |
| Persistent Asset Partners Ltd | 0.63% | 111,226 | +1589% | 0.41% | $1,044,412 |
| ACADIAN ASSET MANAGEMENT LLC | 0.62% | 108,792 | +81% | 0% | $1,016,000 |
| MILLENNIUM MANAGEMENT LLC | 0.61% | 107,800 | +191% | 0% | $1,012,242 |
| VANGUARD FIDUCIARY TRUST CO | 0.54% | 96,241 | 0% | 0% | $903,703 |
| GOLDMAN SACHS GROUP INC | 0.53% | 93,111 | +96% | 0% | $874,313 |
| Seven Fleet Capital Management LP | 0.48% | 85,687 | +51% | 0.25% | $804,601 |
| 683 Capital Management, LLC | 0.48% | 85,543 | 0% | 0.07% | $803,249 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
16
Latest
Q1 2026
Rows shown
1-16 of 16
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 12,828,485 | $120,454,148 | +$569,311 | $9.39 | 107 |
| 2025 Q4 | 13,244,299 | $107,809,776 | +$34,670,041 | $8.14 | 100 |
| 2025 Q3 | 8,624,602 | $109,102,095 | -$2,067,263 | $12.65 | 79 |
| 2025 Q2 | 9,061,852 | $62,525,276 | -$8,932,514 | $6.90 | 78 |
| 2025 Q1 | 10,430,351 | $55,391,632 | -$13,394,437 | $5.31 | 85 |
| 2024 Q4 | 10,952,105 | $129,272,235 | -$16,308,014 | $11.80 | 98 |
| 2024 Q3 | 11,745,584 | $242,331,671 | -$44,650,435 | $20.63 | 106 |
| 2024 Q2 | 10,752,925 | $486,116,698 | +$101,256,908 | $45.25 | 107 |
| 2024 Q1 | 8,529,313 | $334,743,519 | +$310,281,997 | $39.24 | 81 |
| 2023 Q4 | 749,666 | $4,528,896 | +$40,967 | $6.04 | 32 |
| 2023 Q3 | 742,967 | $5,007,338 | +$30,936 | $6.74 | 26 |
| 2023 Q2 | 739,439 | $5,797,676 | +$132,453 | $7.84 | 28 |
| 2023 Q1 | 723,148 | $5,257,408 | +$5,257,398 | $7.27 | 28 |
| 2020 Q2 | 0 | $0 | -$5,240 | $12.15 | 0 |
| 2020 Q1 | 1,000 | $5,240 | $5.24 | 1 | |
| 2019 Q4 | 1,000 | $5,460 | $5.46 | 1 |